查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631257

中低收入国家鸦片类药物替代疗法的全球市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2032年)

Low and Middle Income Countries Opioid Substitution Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032
出版日期: | 出版商: Fairfield Market Research | 英文 200 Pages | 商品交期: 2-5个工作天内

价格
简介目录

中低收入国家的鸦片类药物替代疗法 (OST) 市场规模预计将从 2025 年的 8.556 亿美元增长到 2032 年的 13.91 亿美元，复合年增长率为 7.20%。 OST 透过以美沙酮或丁丙诺啡等受医学监督的替代品取代非法鸦片类药物来减少危害并帮助个人克服毒瘾。 OST 最大限度地降低了过量用药、血源性疾病传播和其他併发症的风险，同时促进了患者重新融入社会。

在中低收入国家，OST 对于解决与鸦片类药物滥用相关的公共卫生课题至关重要。市场成长的动力来自于人们对 OST 有效性的认识不断提高、国际和政府支持以及服务交付方面的创新。市场进入者的机会包括与医疗保健提供者合作，创建具有文化针对性的 OST 解决方案，并利用远距医疗扩大服务不足地区的医疗服务。

由于人们越来越认识到阿片类药物成瘾是一个公共卫生问题，中低收入国家的鸦片类药物替代疗法市场持续成长。各国政府和国际组织的支持有助于OST计画的实施。市场参与者可以透过合作提供可访问的本地化解决方案并采用技术来改善患者的治疗效果，从而抓住机会。

向本报告提供中低收入国家鸦片类药物替代疗法市场相关调查，提供市场概要，以及各类药物，各适应症，各流通管道，各地区趋势，及市场参与市场企业的竞争趋势等资讯。

目录

第1章 摘要整理

第2章 市场概要

  • 市场定义和市场区隔
  • 市场动态
  • 价值链分析
  • 波特的五力分析
  • COVID-19影响分析
  • 经济概要
  • 大环境分析

第3章 价格分析，2019年～2023年

第4章 中低收入国家鸦片类药物替代疗法市场预测，2019年～2032年

  • 中低收入国家鸦片类药物替代疗法市场预测，各类药物，规模(100万美元)，数量(事)，2019年～2032年
  • 中低收入国家鸦片类药物替代疗法市场预测，各适应症，规模(100万美元)，数量(事)，2019年～2032年
  • 中低收入国家鸦片类药物替代疗法市场预测，各流通管道，规模(100万美元)，数量(事)，2019年～2032年
  • 中低收入国家鸦片类药物替代疗法市场预测，各地区，规模(100万美元)，数量(事)，2019年～2032年

第5章 北美的中低收入国家鸦片类药物替代疗法市场预测，2019年～2032年

第6章 欧洲的中低收入国家鸦片类药物替代疗法市场预测，2019年～2032年

第7章 亚太地区的中低收入国家鸦片类药物替代疗法市场预测，2019年～2032年

第8章 南美的中低收入国家鸦片类药物替代疗法市场预测，2019年～2032年

第9章 中东·非洲的中低收入国家鸦片类药物替代疗法市场预测，2019年～2032年

第10章 竞争情形

  • 各解决方案类型和各适应症热图
  • 企业市场占有率分析，2024年
  • 竞争仪表板
  • 企业简介
    • Indivior Inc.
    • Alkermes, Inc
    • Mundipharma GmbH
    • Viatris Inc
    • Intas Pharmaceuticals
    • Camurus

第11章 附录

简介目录

The global Low and Middle Income Countries Opioid Substitution Therapy (OST) Market is projected to grow at a CAGR of 7.20%, increasing from US$ 855.6 million in 2025 to US$ 1,391 million by 2032. OST involves replacing illicit opioids with medically supervised alternatives like methadone or buprenorphine, reducing harm and supporting individuals in overcoming addiction. OST minimizes risks of overdose, blood-borne disease transmission, and other complications while aiding reintegration into society.

In LMICs, OST is vital for addressing public health challenges linked to opioid misuse. The market's growth is fueled by rising awareness of OST's effectiveness, international and governmental support, and innovations in service delivery. Opportunities for market players include partnerships with healthcare providers to create culturally appropriate OST solutions and leveraging telemedicine to expand access in underserved areas.

The OST market in LMICs continues to grow due to increased recognition of opioid addiction as a public health concern. Government and international organization support has bolstered OST program implementation. Market players can capitalize on opportunities by collaborating to deliver accessible, region-specific solutions and incorporating technology to enhance patient outcomes.

Market Growth Drivers

1.Recognition of Public Health Impact

Governments and international health organizations increasingly recognize the burden of opioid addiction. This has led to proactive strategies, with OST emerging as a key harm reduction tool benefiting individuals and communities.

2.Policy Support and Collaboration

Collaborative efforts between governments, NGOs, and international organizations have promoted OST adoption. Supportive policies and integration into healthcare systems ensure broader program reach and impact.

3.Rising Awareness and Healthcare Investments

Increased awareness about opioid addiction and societal impacts, along with healthcare infrastructure investments, drive market growth. Advocacy campaigns promote harm reduction strategies and OST acceptance.

Market Restraints

1.Regulatory Challenges

Diverse regulatory frameworks across LMICs create significant hurdles. Variations in licensing, medication restrictions, and government support hinder OST adoption. Harmonizing regulations is critical for market growth.

2.Implementation Barriers

Limited healthcare infrastructure and insufficient provider training challenge effective OST deployment. Addressing these barriers requires capacity-building initiatives and strategic collaborations.

Business Opportunities

1.Telemedicine Expansion

Telemedicine can improve OST access in regions with limited healthcare infrastructure. Remote consultations and support services address geographical barriers, ensuring consistent care delivery.

2.Strategic Collaborations

Partnerships with healthcare providers, NGOs, and governments can enhance OST delivery. Collaborative efforts like training programs and awareness campaigns foster sustainable healthcare ecosystems.

3.Technological Innovations

Advanced OST solutions tailored to regional needs, such as digital tools for monitoring adherence, present growth potential. Investing in technology-driven systems can improve outcomes and expand market reach.

Regional Analysis

1.Europe

Europe leads the LMICs OST market with progressive harm reduction strategies and strong healthcare systems. Evidence-based policies and collaborations ensure widespread OST adoption. Europe's focus on personalized care and harm reduction establishes it as a model for managing opioid dependence effectively.

2.South Asia and the Pacific

South Asia and the Pacific is the fastest-growing region, driven by health policies and increasing public awareness. Government initiatives, international collaborations, and recognition of OST benefits position this region for rapid expansion.

3.Latin America, Middle East & Africa

Emerging markets in these regions offer untapped opportunities. Increased government efforts and growing investments in healthcare infrastructure drive OST adoption.

Competitive Analysis

Key players in the OST Market include:

  • Indivior Inc.
  • Alkermes, Inc.
  • Mundipharma GmbH
  • Viatris Inc.
  • Intas Pharmaceuticals
  • Camurus

These companies focus on innovation, collaborations, and targeted regional strategies to strengthen their market positions.

Low and Middle Income Countries Opioid Substitution Therapy Market Segmentation

1.By Drug Class

  • Opioid Antagonists
  • Naloxone
  • Naltrexone
  • Opioid Agonists and Partial Agonists
  • Methadone
  • Buprenorphine

2.By Indication

  • Pain Management
  • Opioid Withdrawal/Opioid Use Disorder (OUD)
  • Alcohol De-addiction
  • Depression

3.By Distribution Channel

  • Government-supported Centers/NGOs/Tenders
  • Institutional Sales
  • Hospitals
  • Psychiatric Clinics
  • Retail Pharmacies
  • Online Sales

4.By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Low and Middle Income Countries Opioid Substitution Therapy Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Economic Overview
    • 2.6.1. World Economic Projections
  • 2.7. PESTLE Analysis

3. Price Analysis, 2019 - 2023

  • 3.1. Global Average Price Analysis by Drug Class, 2019 - 2023
  • 3.2. Prominent Factor Affecting Low and Middle Income Countries Opioid Substitution Therapy Prices
  • 3.3. Global Average Price Analysis by Region

4. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 4.1. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Opioid Antagonists
      • 4.1.1.2. Naloxone
      • 4.1.1.3. Naltrexone
      • 4.1.1.4. Opioid Agonists and Partial Agonists
      • 4.1.1.5. Methadone
      • 4.1.1.6. Buprenorphine
  • 4.2. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Pain Management
      • 4.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 4.2.1.3. Alcohol De-addiction
      • 4.2.1.4. Depression
  • 4.3. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Government-supported Centers/NGO's/Tenders
      • 4.3.1.2. Institutional Sales
      • 4.3.1.3. Hospitals
      • 4.3.1.4. Psychiatric clinics
      • 4.3.1.5. Retail Pharmacies
      • 4.3.1.6. Online Sales
  • 4.4. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Region, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. North America
      • 4.4.1.2. Europe
      • 4.4.1.3. Asia Pacific
      • 4.4.1.4. Latin America
      • 4.4.1.5. Middle East & Africa

5. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 5.1. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Opioid Antagonists
      • 5.1.1.2. Naloxone
      • 5.1.1.3. Naltrexone
      • 5.1.1.4. Opioid Agonists and Partial Agonists
      • 5.1.1.5. Methadone
      • 5.1.1.6. Buprenorphine
  • 5.2. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Pain Management
      • 5.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 5.2.1.3. Alcohol De-addiction
      • 5.2.1.4. Depression
  • 5.3. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Government-supported Centers/NGO's/Tenders
      • 5.3.1.2. Institutional Sales
      • 5.3.1.3. Hospitals
      • 5.3.1.4. Psychiatric clinics
      • 5.3.1.5. Retail Pharmacies
      • 5.3.1.6. Online Sales
    • 5.3.2. Attractiveness Analysis
  • 5.4. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.2. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.3. U.S. Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.4. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.5. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 5.4.1.6. Canada Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

6. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 6.1. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Opioid Antagonists
      • 6.1.1.2. Naloxone
      • 6.1.1.3. Naltrexone
      • 6.1.1.4. Opioid Agonists and Partial Agonists
      • 6.1.1.5. Methadone
      • 6.1.1.6. Buprenorphine
  • 6.2. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Pain Management
      • 6.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 6.2.1.3. Alcohol De-addiction
      • 6.2.1.4. Depression
  • 6.3. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Government-supported Centers/NGO's/Tenders
      • 6.3.1.2. Institutional Sales
      • 6.3.1.3. Hospitals
      • 6.3.1.4. Psychiatric clinics
      • 6.3.1.5. Retail Pharmacies
      • 6.3.1.6. Online Sales
    • 6.3.2. Attractiveness Analysis
  • 6.4. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.2. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.3. Germany Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.4. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.5. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.6. U.K. Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.7. France Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.8. France Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.9. France Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.10. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.11. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.12. Italy Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.13. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.14. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.15. Turkey Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.16. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.17. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.18. Russia Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.19. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.20. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 6.4.1.21. Rest of Europe Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

7. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 7.1. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Opioid Antagonists
      • 7.1.1.2. Naloxone
      • 7.1.1.3. Naltrexone
      • 7.1.1.4. Opioid Agonists and Partial Agonists
      • 7.1.1.5. Methadone
      • 7.1.1.6. Buprenorphine
  • 7.2. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Pain Management
      • 7.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 7.2.1.3. Alcohol De-addiction
      • 7.2.1.4. Depression
  • 7.3. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Government-supported Centers/NGO's/Tenders
      • 7.3.1.2. Institutional Sales
      • 7.3.1.3. Hospitals
      • 7.3.1.4. Psychiatric clinics
      • 7.3.1.5. Retail Pharmacies
      • 7.3.1.6. Online Sales
    • 7.3.2. Attractiveness Analysis
  • 7.4. Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. China Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.2. China Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.3. China Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.4. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.5. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.6. Japan Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.7. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.8. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.9. South Korea Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.10. India Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.11. India Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.12. India Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.13. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.14. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.15. Southeast Asia Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.16. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.17. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 7.4.1.18. Rest of Asia Pacific Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

8. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 8.1. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Opioid Antagonists
      • 8.1.1.2. Naloxone
      • 8.1.1.3. Naltrexone
      • 8.1.1.4. Opioid Agonists and Partial Agonists
      • 8.1.1.5. Methadone
      • 8.1.1.6. Buprenorphine
  • 8.2. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Pain Management
      • 8.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 8.2.1.3. Alcohol De-addiction
      • 8.2.1.4. Depression
  • 8.3. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Government-supported Centers/NGO's/Tenders
      • 8.3.1.2. Institutional Sales
      • 8.3.1.3. Hospitals
      • 8.3.1.4. Psychiatric clinics
      • 8.3.1.5. Retail Pharmacies
      • 8.3.1.6. Online Sales
    • 8.3.2. Attractiveness Analysis
  • 8.4. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.2. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.3. Brazil Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.4. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.5. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.6. Mexico Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.7. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.8. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.9. Argentina Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.10. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.11. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 8.4.1.12. Rest of Latin America Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

9. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, 2019 - 2032

  • 9.1. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Opioid Antagonists
      • 9.1.1.2. Naloxone
      • 9.1.1.3. Naltrexone
      • 9.1.1.4. Opioid Agonists and Partial Agonists
      • 9.1.1.5. Methadone
      • 9.1.1.6. Buprenorphine
  • 9.2. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Pain Management
      • 9.2.1.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
      • 9.2.1.3. Alcohol De-addiction
      • 9.2.1.4. Depression
  • 9.3. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Government-supported Centers/NGO's/Tenders
      • 9.3.1.2. Institutional Sales
      • 9.3.1.3. Hospitals
      • 9.3.1.4. Psychiatric clinics
      • 9.3.1.5. Retail Pharmacies
      • 9.3.1.6. Online Sales
    • 9.3.2. Attractiveness Analysis
  • 9.4. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.2. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.3. GCC Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.4. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.5. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.6. South Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.7. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.8. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.9. Egypt Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.10. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.11. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.12. Nigeria Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.13. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.14. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Indication, Value (US$ Mn) and Volume (Units), 2019 - 2032
      • 9.4.1.15. Rest of Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market by Distribution Channel, Value (US$ Mn) and Volume (Units), 2019 - 2032

10. Competitive Landscape

  • 10.1. By Solution Type vs by Indication Heatmap
  • 10.2. Company Market Share Analysis, 2024
  • 10.3. Competitive Dashboard
  • 10.4. Company Profiles
    • 10.4.1. Indivior Inc.
      • 10.4.1.1. Company Overview
      • 10.4.1.2. Product Portfolio
      • 10.4.1.3. Financial Overview
      • 10.4.1.4. Business Strategies and Development
    • 10.4.2. Alkermes, Inc
      • 10.4.2.1. Company Overview
      • 10.4.2.2. Product Portfolio
      • 10.4.2.3. Financial Overview
      • 10.4.2.4. Business Strategies and Development
    • 10.4.3. Mundipharma GmbH
      • 10.4.3.1. Company Overview
      • 10.4.3.2. Product Portfolio
      • 10.4.3.3. Financial Overview
      • 10.4.3.4. Business Strategies and Development
    • 10.4.4. Viatris Inc
      • 10.4.4.1. Company Overview
      • 10.4.4.2. Product Portfolio
      • 10.4.4.3. Financial Overview
      • 10.4.4.4. Business Strategies and Development
    • 10.4.5. Intas Pharmaceuticals
      • 10.4.5.1. Company Overview
      • 10.4.5.2. Product Portfolio
      • 10.4.5.3. Financial Overview
      • 10.4.5.4. Business Strategies and Development
    • 10.4.6. Camurus
      • 10.4.6.1. Company Overview
      • 10.4.6.2. Product Portfolio
      • 10.4.6.3. Financial Overview
      • 10.4.6.4. Business Strategies and Development

11. Appendix

  • 11.1. Research Methodology
  • 11.2. Report Assumptions
  • 11.3. Acronyms and Abbreviations